Radioimmunotherapy versus autologous hematopoietic stem cell transplantation in relapse/refractory follicular lymphoma: a Fondazione Italiana Linfomi multicenter, randomized, phase 3 trial.

Zanubrutinib plus obinutuzumab (ZO) versus obinutuzumab (O) monotherapy in patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL): Primary analysis of the phase 2 randomized ROSEWOOD trial.

(2022) Pier Luigi Zinzani et al.   JOURNAL OF CLINICAL ONCOLOGY

IBCL-249 Mosunetuzumab Monotherapy Is an Effective and Well-Tolerated Treatment Option for Patients With Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Who Have Received ≥2 Prior Lines of Therapy: Pivotal Results From a Phase I/II Study

(2022) Elizabeth L Budde et al.   Clinical Lymphoma Myeloma & Leukemia

Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell–Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial

(2021) Martin Hutchings et al.   JOURNAL OF CLINICAL ONCOLOGY

Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial

(2021) Caron A Jacobson et al.   LANCET ONCOLOGY

PI3K Inhibitors and Their Role as Novel Agents for Targeted Therapy in Lymphoma

(2020) Vladimir Sapon-Cousineau et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups

(2020) Connie L. Batlevi et al.   Blood Cancer Journal

Long Term Follow-Up of Lenalidomide and Rituximab as Initial Treatment of Follicular Lymphoma

(2020) Paolo Strati et al.   BLOOD

Phase 1/2a study of 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma

(2020) Arne Kolstad et al.   Blood Advances

Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2020) M. Dreyling et al.   ANNALS OF ONCOLOGY

AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma

(2019) John P. Leonard et al.   JOURNAL OF CLINICAL ONCOLOGY

Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study

(2019) Emmanuel Bachy et al.   JOURNAL OF CLINICAL ONCOLOGY

Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study

(2019) Franck Morschhauser et al.   Lancet Haematology

Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis

(2018) Carla Casulo et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma

(2018) Stefano Luminari et al.   JOURNAL OF CLINICAL ONCOLOGY

Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma

(2018) Franck Morschhauser et al.   NEW ENGLAND JOURNAL OF MEDICINE

Management of febrile neutropaenia: ESMO Clinical Practice Guidelines†

(2016) J. Klastersky et al.   ANNALS OF ONCOLOGY

The 2016 revision of the World Health Organization classification of lymphoid neoplasms

(2016) S. H. Swerdlow et al.   BLOOD

Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update

(2015) Thomas J. Smith et al.   JOURNAL OF CLINICAL ONCOLOGY

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

(2013) Mathias J Rummel et al.   LANCET

The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications

(2011) E. Campo et al.   BLOOD

Safety and Efficacy of Combination Therapy with Fludarabine, Mitoxantrone, and Rituximab Followed by Yttrium-90 Ibritumomab Tiuxetan and Maintenance Rituximab as Front-Line Therapy for Patients With Follicular or Marginal Zone Lymphoma

(2011) Reem Karmali et al.   Clinical Lymphoma Myeloma & Leukemia

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial

(2010) Gilles Salles et al.   LANCET

Phase III Trial of Consolidation Therapy With Yttrium-90–Ibritumomab Tiuxetan Compared With No Additional Therapy After First Remission in Advanced Follicular Lymphoma

(2008) Franck Morschhauser et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Study of R-CVP Compared With Cyclophosphamide, Vincristine, and Prednisone Alone in Patients With Previously Untreated Advanced Follicular Lymphoma

(2008) Robert Marcus et al.   JOURNAL OF CLINICAL ONCOLOGY